Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 2, 2008, Pages 264-275

  Bateman, E D ^a   Linnhof, A E ^b   Homik, L ^c   Freudensprung, U ^c   Smau, L ^c   Engelstatter R ^c  

^a Faculty of Health Sciences   (South Africa)

^b Concordia Hospital ^*

^c ALTANA PHARMA AG   (Germany)

Author keywords

Ciclesonide; Fluticasone propionate; Lung function; Oral candidiasis; Persistent asthma; Quality of life

Indexed keywords

CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLUENZA; LUNG FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; SYMPTOM; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PREGNENEDIONES; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 39749127770     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.05.002     Document Type: Article

References (38)

1. NIH. National Institutes of Health National Heart Lung and Blood Institute. National asthma education and prevention program. Expert panel report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics. J Allergy Clin Immunol 2002; 110: S141-S219.
2. GINA. Global Initiative for Asthma. National Institutes of Health, National Heart, Lung and 338 Blood Institute. 〈www.ginasthma.com〉. 2005.
3. Allen D.B., Bielory L., Derendorf H., Dluhy R., Colice G.L., and Szefler S.J. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 112 3 Suppl (2003) S1-S40
4. Cave A., Arlett P., and Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 83 3 (1999) 153-179
5. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 9 (1999) 941-955
6. Roland N., Bhalla R., and Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 126 (2004) 213-219
7. Dubus J.C., Marguet C., Deschildre A., Mely L., Le Roux P., Brouard J., et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 56 10 (2001) 944-948
8. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guideline-defined asthma control be achieved?. Am J Resp Crit Care Med 170 (2004) 836-844
9. Masoli M., Weatherall M., and Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology 10 2 (2005) 183-188
10. Purucker M.E., Rosebraugh C.J., Zhou F., and Meyer R.J. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 124 4 (2003) 1584-1593
11. Postma D.S., Sevette C., Martinat Y., Schlosser N., Aumann J., and Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 6 (2001) 1083-1088
12. Chapman K.R., Patel P., D'Urzo A.D., Alexander M., Mehra S., Oedekoven C., et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60 3 (2005) 330-337
13. Langdon C.G., Adler M., Mehra S., Alexander M., and Drollmann A. Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99 (2005) 1275-1285
14. Dietzel K., Engelstätter R., and Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 31 (2001) 91-93
15. Stoeck M., Riedel R., Hochhaus G., Hafner D., Masso J.M., Schmidt B., et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 309 1 (2004) 249-258
16. Rohatagi S., Luo Y., Shen L., Guo Z., Schemm C., Huang Y., et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12 3 (2005) 201-209
17. Nave R., Bethke T., Marle S.v., and Zech K. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43 7 (2004) 479-486
18. Nave R., Meyer W., Fuhst R., and Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 18 6 (2005) 390-396
19. Buhl R., Vinkler I., Magyar P., Gyori Z., Rybacki C., Middle M.V., et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 19 6 (2006) 404-412
20. ®) in patients with moderate asthma. Proc Am Thorac Soc 3 Suppl. (2006) A73
21. Magnussen H., Hofman J., Novakova B., Kaczmarek B., Hellwig B., and Engelstaetter R. Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients. Eur Respir J 1736 (2005) 255 s
22. Juniper E., Guyatt G., Epstein R., Ferrie P., Jaeschke R., and Hiller T. Evaluation of impairment of health-related quality in asthma: development of a questionnaire for use in clinical trials. Thorax 47 (1992) 76-83
23. Juniper E., Buist A., Cox F., Ferrie P., and King D. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 115 (1999) 1265-1270
24. Pearlman D., Berger W., Kerwin E., LaForce C., Kundu S., and Banerjee D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116 6 (2005) 1206-1212
25. Lee D.K., Haggart K., Currie G.P., Bates C.E., and Lipworth B.J. Effects of hydrofluoroalkane formulations of ciclesonide 400 microgram once daily vs fluticasone 250 micro g twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 58 1 (2004) 26-33
26. Derom E., van De Velde V., Marissens S., Engelstätter R., Vincken W., and Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 18 5 (2005) 328-336
27. Lee D.K., Fardon T.C., Bates C.E., Haggart K., McFarlane L.C., and Lipworth B.J. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 127 3 (2005) 851-860
28. Zietkowski Z., Bodzenta-Lukaszyk A., Tomasiak M.M., Szymanski W., and Skiepko R. Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir Med 100 9 (2006) 1651-1656
29. Adams N., Bestall J.M., Lasserson T.J., and Jones P.W. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2 (2005) CD002310
30. Niphadkar P., Jagannath K., Joshi J.M., Awad N., Boss H., Hellbardt S., et al. Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 27 11 (2005) 1752-1763
31. Boulet L.P., Drollmann A., Magyar P., Timar M., Knight A., Engelstätter R., et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 100 5 (2006) 785-794
32. Settipane R.A. Defining the effects of an inhaled corticosteroid and long-acting beta-agonist on therapeutic targets. Allergy Asthma Proc 24 2 (2003) 85-89
33. Richter K., Kanniess F., Biberger C., Nave R., and Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45 2 (2005) 146-152
34. Agertoft L., and Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115 5 (2005) 940-945
35. Lipworth B.J., Kaliner M.A., LaForce C.F., Baker J.W., Kaiser H.B., Amin D., et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94 4 (2005) 465-472
36. Szefler S., Rohatagi S., Williams J., Lloyd M., Kundu S., and Banerji D. Ciclesonide, a novel inhaled steroid, does not affect HPA-axis function in patients with moderate-to-severe persistent asthma. Chest 128 (2005) 1104-1114
37. Skoner D., Maspero J., Kundu S., Lloyd M., and Banerji D. Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol 117 2 (2006) S11
38. Global asthma physician and patient (GAPP) survey 2006. 〈www.gappsurvey.org〉. Last accessed June 2006.